Drug Trial Radar · NCT05586958
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
Last checked: Nov 20, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
354
Actual
Start
Oct 25, 2022
Primary completion
Nov 4, 2024
Study completion Dec 16, 2024
Sponsor
- Lead sponsor
- LG ChemIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Conditions
- Gout
- Hyperuricemia
- Gout Flare
- Tophi
Interventions
TigulixostatDrug
Xanthine Oxidase Inhibitor
PlaceboDrug
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects with sUA levels <6.0 mg/dL sustained at months 4, 5, and 6Time frame: Up to Month 6
Locations
52 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Medvin Clinical Research
Covina, California
Clinical Research of West Florida, Inc.
Clearwater, Florida
Herco Medical and Research Center, Inc
Coral Gables, Florida
Direct Helpers Research Center
Hialeah, Florida
Allied Biomedical Research Institute
Miami, Florida
Research Institute of South Florida, Inc.
Miami, Florida
Clinical Research of West Florida, Inc.
Tampa, Florida
Conquest Research, LLC
Winter Park, Florida
Vista Clinical Research, LLC
Newnan, Georgia
Velocity Clinical Research
Meridian, Idaho
Healthcare Research Network II, LLC
Flossmoor, Illinois
Alliance for Multispecialty Research, LLC
Lexington, Kentucky
L-MARC Research Center
Louisville, Kentucky
MD Medical Research
Oxon Hill, Maryland
Elite Clinical Research, LLC
Jackson, Mississippi
Olive Branch Family Medical Center
Olive Branch, Mississippi
Practice Dr. David Headley
Port Gibson, Mississippi
HealthCare Research
Hazelwood, Missouri
Healor Primary Care/CCT Research
Las Vegas, Nevada
Meridian Clinical Research, LLC
Vestal, New York
Triad Clinical Trials
Greensboro, North Carolina
STAT Research
Vandalia, Ohio
Altoona Center for Clinical Research
Duncansville, Pennsylvania
Tristar Clinical Investigations, P.C.
Philadelphia, Pennsylvania
Velocity Clinical Research Greenville
Greenville, South Carolina
PCCR Solutions
Colleyville, Texas
Pioneer Research Solutions, Inc.
Houston, Texas
Endeavor Clinical Trials
San Antonio, Texas
DM Clinical Research
Tomball, Texas
Highland Clinical Research
Salt Lake City, Utah
South Ogden Family Medicine/CCT Research
South Ogden, Utah
Velocity Clinical Research, Salt Lake City
West Jordan, Utah
Meridian Clinical Research, LLC
Portsmouth, Virginia
Dominion Medical Associates, Inc.
Richmond, Virginia
Clinical Research Partners, LLC
Richmond, Virginia
LTD "Clinic LJ"
Kutaisi, Georgia
Aleksandre Aladashvili Clinic LLC
Tbilisi, Georgia
LTD Israel-Georgian Medical Research Clinic Helsicore
Tbilisi, Georgia
JSC "Vian"
Tbilisi, Georgia
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.